LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

ConditionSarcoma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

AgeNot listed

SponsorWake Forest University Health Sciences

About this trial

The purpose of this research study is to see how well Low Pass Whole Genome Sequencing (LP-WGS) can detect circulating tumor deoxyribonucleic acid (ctDNA) in the blood of participants who have bone or soft tissue sarcoma (type of cancer).

Eligibility criteria

Qualifiers

Written informed consent or assent when applicable from the participant, LAR, parent or legal guardian and HIPAA authorization for release of personal health information.

All ages allowed

Suspected bone or soft tissue tumor concerning for sarcoma (pending confirmation of sarcoma diagnosis)

Suspected lipomatous mass concerning for ALT or WDLS with planned surgery

Disqualifiers

none

Trial design

Treatments tested in this trial

Non-Metastatic and Resectable
Metastatic and Un-resectable
No evidence of disease, under surveillance
ALT or WDLS

Treatment groups

300 Participants

are divided into 4 treatment groups

Sponsors and collaborators

Wake Forest University Health Sciences

Lead sponsor

Paula Takacs Foundation

Collaborator

Source ClinicalTrials.gov